Overview

PK and PD Study of NPI-001 and Cysteamine Bitartrate

Status:
Recruiting
Trial end date:
2024-06-21
Target enrollment:
Participant gender:
Summary
Safety, pharmacokinetics, and pharmacodynamics of NPI-001 oral solution in cystinosis patients compared with cysteamine.
Phase:
Phase 1/Phase 2
Details
Lead Sponsor:
Nacuity Pharmaceuticals, Inc.
Treatments:
Acetylcysteine
Cysteamine
N-monoacetylcystine